tafoxiparin

Tafoxiparin is a proprietary, depolymerized form of heparin developed to eliminate the anticoagulant effects typically associated with heparin. It is a low molecular weight glycosaminoglycan that mimics endogenous heparan sulfate but lacks significant anti-coagulant activity. The drug is primarily being developed for obstetric indications, specifically for cervical ripening and labor augmentation in term pregnant women, aiming to induce spontaneous onset of labor and reduce complications for both mother and infant. Unlike traditional methods requiring hospitalization or mechanical/pharmacological interventions, tafoxiparin can be self-administered at home via daily subcutaneous injection using an autoinjector. Mechanistically, it acts as a muscle protein modulator by promoting cervical ripening and myometrial remodeling over several days, thereby priming the natural process of labor initiation. Additionally, preclinical research has explored its potential as an inhibitor of SARS-CoV-2 spike protein binding due to structural similarities with heparan sulfate; however, no clinical development has been reported in this area[1][3][4][6][8].

Other names

DF 01DF01DF-01tafoxiparin